157 related articles for article (PubMed ID: 26625703)
1. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases.
Furtmann N; Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Bajorath J; Gütschow M
Chemistry; 2016 Jan; 22(2):610-25. PubMed ID: 26625703
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Beckmann AM; Gilberg E; Gattner S; Huang TL; Vanden Eynde JJ; Mayence A; Bajorath J; Stirnberg M; Gütschow M
Bioorg Med Chem Lett; 2016 Aug; 26(15):3741-5. PubMed ID: 27287367
[TBL] [Abstract][Full Text] [Related]
3. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
[TBL] [Abstract][Full Text] [Related]
4. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Enyedy IJ; Lee SL; Kuo AH; Dickson RB; Lin CY; Wang S
J Med Chem; 2001 Apr; 44(9):1349-55. PubMed ID: 11311057
[TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
6. A Bisbenzamidine Phosphonate as a Janus-faced Inhibitor for Trypsin-like Serine Proteases.
Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Gütschow M
ChemMedChem; 2015 Oct; 10(10):1641-6. PubMed ID: 26306030
[TBL] [Abstract][Full Text] [Related]
7. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
8. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
9. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases.
Katz BA; Luong C
J Mol Biol; 1999 Sep; 292(3):669-84. PubMed ID: 10497030
[TBL] [Abstract][Full Text] [Related]
10. Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Goswami R; Wohlfahrt G; Mukherjee S; Ghadiyaram C; Nagaraj J; Satyam LK; Subbarao K; Gopinath S; Krishnamurthy NR; Subramanya HS; Ramachandra M
Bioorg Med Chem Lett; 2015 Feb; 25(3):616-20. PubMed ID: 25556099
[TBL] [Abstract][Full Text] [Related]
11. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
12. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Häußler D; Mangold M; Furtmann N; Braune A; Blaut M; Bajorath J; Stirnberg M; Gütschow M
Chemistry; 2016 Jun; 22(25):8525-35. PubMed ID: 27214780
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
[TBL] [Abstract][Full Text] [Related]
14. Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Goswami R; Mukherjee S; Ghadiyaram C; Wohlfahrt G; Sistla RK; Nagaraj J; Satyam LK; Subbarao K; Palakurthy RK; Gopinath S; Krishnamurthy NR; Ikonen T; Moilanen A; Subramanya HS; Kallio P; Ramachandra M
Bioorg Med Chem; 2014 Jun; 22(12):3187-203. PubMed ID: 24794746
[TBL] [Abstract][Full Text] [Related]
15. Oxyanion-mediated inhibition of serine proteases.
Presnell SR; Patil GS; Mura C; Jude KM; Conley JM; Bertrand JA; Kam CM; Powers JC; Williams LD
Biochemistry; 1998 Dec; 37(48):17068-81. PubMed ID: 9836602
[TBL] [Abstract][Full Text] [Related]
16. Understanding binding selectivity toward trypsin and factor Xa: the role of aromatic interactions.
Di Fenza A; Heine A; Koert U; Klebe G
ChemMedChem; 2007 Mar; 2(3):297-308. PubMed ID: 17191291
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Li P; Jiang S; Lee SL; Lin CY; Johnson MD; Dickson RB; Michejda CJ; Roller PP
J Med Chem; 2007 Nov; 50(24):5976-83. PubMed ID: 17985858
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of human factor Xa complexed with potent inhibitors.
Maignan S; Guilloteau JP; Pouzieux S; Choi-Sledeski YM; Becker MR; Klein SI; Ewing WR; Pauls HW; Spada AP; Mikol V
J Med Chem; 2000 Aug; 43(17):3226-32. PubMed ID: 10966741
[TBL] [Abstract][Full Text] [Related]
19. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
20. Ligand-receptor 3-D similarity studies using multiple 4-point pharmacophores.
Mason JS; Cheney DL
Pac Symp Biocomput; 1999; ():456-67. PubMed ID: 10380219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
